4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
| Revenue (Most Recent Fiscal Year) | $85.21M |
| Net Income (Most Recent Fiscal Year) | $-140.11M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.65 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -182.34% |
| Net Margin (Trailing 12 Months) | -182.34% |
| Return on Equity (Trailing 12 Months) | -36.83% |
| Return on Assets (Trailing 12 Months) | -32.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.34 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.85 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.01 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.42 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 52.28M |
| Free Float | 48.15M |
| Market Capitalization | $498.19M |
| Average Volume (Last 20 Days) | 0.76M |
| Beta (Past 60 Months) | 2.75 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.27% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |